Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy.
暂无分享,去创建一个
[1] A. Bezjak,et al. Predicting Radiation Esophagitis Using 18F‐FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] Y. Ohe,et al. Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. , 2016, International journal of radiation oncology, biology, physics.
[3] W. Weber,et al. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. , 2015, Clinical lung cancer.
[4] J. Bradley,et al. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. , 2015, International journal of radiation oncology, biology, physics.
[5] D. Sher,et al. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0–2) Non–Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] S. Hyun,et al. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. , 2015, AJR. American journal of roentgenology.
[7] V. Grégoire,et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] Jan-Jakob Sonke,et al. Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] C. Brink,et al. Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer , 2014, Acta oncologica.
[10] J. Aerts,et al. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] P. Baas,et al. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. , 2013, Clinical lung cancer.
[12] J. Sonke,et al. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] Shalini K Vinod,et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] R. Rami-Porta,et al. Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the Staging Project Database of the International Association for the Study of Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] Jan-Jakob Sonke,et al. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. , 2012, International journal of radiation oncology, biology, physics.
[16] Jan-Jakob Sonke,et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] Maria Werner-Wasik,et al. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. , 2011, Clinical lung cancer.
[18] N. O'Rourke,et al. Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.
[19] Jose Belderbos,et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Oyen,et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[21] Joos V Lebesque,et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. , 2005, European journal of cancer.
[22] Joos V Lebesque,et al. Inclusion of geometric uncertainties in treatment plan evaluation. , 2002, International journal of radiation oncology, biology, physics.